Introduction
HLA-DRB1 alleles that code a 'shared epitope' -a five amino acid sequence motif in residues 70-74 of the human leukocyte antigen (HLA)-DRb chain -are associated with severe rheumatoid arthritis (RA, [1-4]). The better-known shared epitope-coding alleles include members of the HLA-DRB1Ã04 allele group (e.g. Ã0401, Ã0404, Ã0405 and Ã0408), HLA-DRB1Ã0101 or Ã0102, HLA-DRB1Ã1402 and HLA-DRB1Ã1001. Additional alleles are listed in Table 1 . The purpose of this review is to discuss some publications in the past 12 months that could help advance our understanding of the role of the shared epitope in RA.
The shared epitope hypothesis: work in progress
The mechanism underlying shared epitope-RA association is unclear. The common hypotheses attribute it to the presentation of arthritogenic antigens [5] or T-cell repertoire selection [6] . However, it should be pointed out that data supporting antigen-specific immune responses as the primary event in RA are inconclusive. Additionally, several non-RA human diseases [7] [8] [9] [10] [11] [12] and experimental animal models of autoimmunity [13] [14] [15] [16] have been shown to associate with shared epitope-coding alleles as well. Furthermore, the antigenpresentation hypothesis is difficult to reconcile with shared epitope allele-dose effects on RA penetrance and disease severity (discussed in [17] ).
Unlike the uncertain mechanism, the association itself has remained largely unchallenged for more than two decades. One notable refinement of the proposed shared epitope motif, however, relates to position 70 of the DRb chain. In addition to what has been long considered, current evidence suggests that although glutamine or arginine at position 70 are indeed critical for RA risk, aspartic acid at that position confers protection [18] . To 
Recent findings
New evidence has been recently presented to suggest that noninherited human leukocyte antigens (HLAs) originating through pregnancy or exposure to maternal antigens in utero could contribute to RA development in shared epitope-negative women. An interaction between smoking and shared epitope-coding non-Ã04 HLA-DRB1 alleles (particularly HLA-DRB1Ã01 and HLA-DRB1Ã10) was formally established for the first time. Progress has been made in determining the relative contributions and the interaction of the shared epitope, PTPN22 and smoking in conferring the risk of anticitrullinated protein antibodies-positive and negative RA. The autoantigen that anticitrullinated protein antibodies recognize in a significant number of RA patients has been identified as citrullinated a-enolase and the importance of genetic factors in anticitrullinated protein antibodies-negative RA has been highlighted. Additionally, associations of RA risk with several new genetic markers have been reported. Among them: two new major histocompatibility complex, non-DRB1 loci, a polymorphism marker in major histocompatibility complex class I polypeptide-related sequence A, an allele of the Fcg receptor, a polymorphism marker in the b2-adrenergic receptor and a low-inducible allele of the cytochrome P450 subtype 1A2. Summary Although the mechanistic basis of shared epitope-RA association remains an enigma, observations made during the last year shed new light on the conditions in which the shared epitope -alone or in combination with other genes or environmental factorsaffects the risk of RA and the phenotype of the disease. further define structure-phenotype relationships on the DRb 70-74 region, Carrier et al. [19 ] have recently studied the effect of the DERAA sequence (residues 70-74 encoded by several HLA-DRB1 alleles, including the RA-protective HLA-DRBÃ0402 allele) on disease outcomes in patients with early arthritis. Their data showed that in patients without early erosions, DERAA-coding DRB1 alleles were strongly protective against severe disease at 30 months. Thus, in addition to prior indications that aspartic acid at position 70 may reduce RA risk, it now appears that it may also reduce disease severity. How this effect is consistent with the antigen-presentation theory remains a mystery.
It is estimated that up to 20% of RA patients are shared epitope-negative. The possibility that noninherited maternal HLA antigens (NIMA) could explain RA development in these individuals has been examined previously but yielded inconclusive results. In 2009, however, two studies provided new evidence that could support a role for noninherited HLA antigens. Examining a large cohort of families from the North American Rheumatoid Arthritis Consortium, Guthrie et al. [20 ] have found a significant association between RA risk and HLA-DR4-coding NIMA in women less than 45 years of age, but not in older women, or men. Along the same lines, a European group [21 ] has recently demonstrated that compared with healthy women, RA female patients had a higher frequency and higher levels of HLA-DRB1Ã04 microchimerism. The prevalence of noninherited genes in larger patient populations and their pathogenic mechanism are unknown.
The shared epitope and citrullinated proteins
Genetic factors, with the shared epitope being the strongest among them, play a significant role in RA susceptibility. Intriguingly, despite the major role of genetic factors in RA susceptibility, the concordance rate of this disease in monozygotic twins is only 15% [22] . It has been, therefore, hypothesized that although RA susceptibility is determined genetically, disease onset may depend on nongenetic (i.e. environmental), epigenetic or posttranslational events.
Deimination of arginine to citrulline by peptidyl arginine deiminase (PADI) is one of the better-characterized posttranslational protein modifications in RA. Several citrullinated proteins have been identified in the disease [23] [24] [25] . However, the significance of citrullination remains unclear because deiminated proteins have also been found in target tissues of non-RA inflammatory diseases as well as noninflammatory conditions (reviewed in [26] ).
Over the last few years, anticitrullinated protein antibodies (ACPAs) have been convincingly shown to be specific serological markers for RA, particularly in shared epitope-positive patients. These observations have lead many to propose that ACPA may be playing a direct pathogenic role in RA. Experimental data to support this hypothesis have been reported in some arthritis models (e.g. [27, 28] ). However, other animal studies [29] [30] [31] have failed to demonstrate direct involvement of anticitrullinated proteins immunity in experimental arthritis. In human RA, likewise, there is presently no conclusive evidence to directly implicate ACPA as an effector mechanism in disease pathogenesis.
Relevant to the focus of this review, ACPA are found in shared epitope-positive, but rarely in shared epitopenegative, RA patients [32] . Furthermore, a shared epitope gene-dose effect on RA risk has been documented in ACPA-positive RA patients [33] . On the basis of these findings and a reported high-affinity interaction between citrullinated peptides and shared epitope-positive HLA-DR molecules [34] , it has been hypothesized that the association between shared epitope and ACPA represents shared epitope-restricted presentation of citrullinated antigen(s). It should be noted, however, that the identities of such putative antigens remain unknown and there are no RA-relevant functional data to substantiate 294 Rheumatoid arthritis this hypothesis to date. Moreover, a recent study [35] has shown that antibodies against PADI4 are also highlyspecific for RA, raising the possibility that antigenically diverse targets within the PADI pathway are peculiarly immunogenic and arguing against antigen-specific effector role of ACPA. Additionally, recognition of a sequenceindependent posttranslational modification, rather than a bona fide antigenic epitope, is inconsistent with what is widely considered MHC-restricted antigen-specific recognition. Finally, as discussed above, the antigen presentation paradigm is inconsistent with the promiscuous shared epitope disease association, and the observed shared epitope gene-dose effects on disease susceptibility, penetrance and severity (reviewed in [17] ).
The cosegregation of ACPA positivity and shared epitope-coding alleles among RA patients has continued to attract research attention in 2009. Several studies focusing on the genetic basis of ACPA positivity or negativity have been published. For example, one study [36 ] quantified the contribution of genetic risk factors, particularly the shared epitope, to ACPA-positive versus negative RA by computing their heritability in 148 RA twin pairs in which at least one twin had the disease. Comparable heritability rates were found in the ACPApositive and negative RA subsets. However, the presence of shared epitope explained 18% of the genetic variance in ACPA-positive individuals, but it contributed only 2.4% of the variance in the ACPA-negative group. The authors concluded that although genetic predisposition plays a significant role in susceptibility to both types of RA, the development of an ACPA-negative disease depends on as yet unidentified non-shared epitope genetic factors.
The identity of putative genetic modulators of ACPA positivity in RA has been reported by Lundströ m et al. [37 ] . In that study, a case-control analysis of 1352 RA patients and 922 controls revealed that DRB1Ã13 has a dual role: it protects against ACPA-positive RA, but, in combination with DRB1Ã03, it increases the risk of ACPA-negative disease. Partial corroboration of the putative role of DRB1Ã03 was obtained in a recent study [38] that carried out a genome-wide association analysis of ACPA titers in RA. That study confirmed that HLA is the most important gene region for ACPA in RA. Further, the two top single-nucleotide polymorphism (SNP) markers, which associated inversely with ACPA titer, were found to be in moderate linkage disequilibrium with DRB1Ã03 alleles, which have been previously found to associate with low ACPA titers [39] .
Shared epitope-environment interaction
As discussed above, it is widely believed that cooperation between genetic and environmental factors is required for RA disease onset. Consistent with this model, a geneenvironment interaction between the shared epitope and smoking has been reported by several groups prior to 2009 [40, 41] . For example, a highly significant interaction between the shared epitope and smoking in RA risk has been reported by a Swedish group, particularly in shared epitope homozygous individuals [40] . Similar conclusions have been reached by a more recent Danish study [41] . Different from the North European studies, early reports on shared epitope-smoking interaction in US populations had been inconclusive. However, in early 2009, a very large US study [42 ] suggested that similar interactions exist in North Americans as well. Studying over 60 000 individuals, the authors have demonstrated strong gene-environment interaction between the shared epitope and smoking when stratifying by pack-years of smoking rather than by ever smoking. This US study shows that the extent of the exposure is important and corroborates the role of shared epitope-smoking interactions previously observed only in North European patient populations. Thus, there is compelling evidence for interaction between the shared epitope and tobacco exposure in the cause of RA in different geographic locations across the globe.
Previously reported interactions between the shared epitope and smoking have largely focused on the DRB1Ã04 alleles. In a paper [43 ] published in mid-2009, the spectrum of shared epitope-coding alleles was expanded to include DRB1Ã01 and DRB1Ã10. The study concluded that a strong interaction between smoking and shared epitope in the development of ACPA-positive RA exists in all the shared epitope-coding alleles tested (DRB1Ã04, DRB1Ã01 and DRB1Ã10). Whether other shared epitopepositive alleles (e.g. DRB1Ã1402) show the same interaction remains to be determined.
Previous studies have suggested that the interaction between the shared epitope and smoking results primarily in anticitrulline immunity. In an attempt to formally address this question, Morgan et al. [44 ] examined the interactions between the shared epitope, PTPN22 and smoking in the development of ACPA-positive and negative RA, in a cohort of approximately 5000 patients and 3700 controls. Their results suggested that although PTPN22 primarily associated with ACPA positivity, the shared epitope was found to be independently associated with rheumatoid factor.
The antigenic specificity of ACPA in gene-environment interactions has been examined in a recent study [45 ] . Here, the authors determined to what extent autoimmunity to citrullinated a-enolase accounts for the observed associations among smoking, shared epitope, PTPN22 and ACPA. Antibodies to this autoantigen were found in 43-63% of ACPA-positive RA patients. Citrullinated
The rheumatoid arthritis HLA-DRB1 shared epitope Holoshitz 295 a-enolase reactivity marked a subpopulation with a very strong odds ratio (OR) for RA development, when the combined effect of shared epitope, smoking and PTPN22 was considered. The ACPA-positive, citrullinated a-enolase-negative subpopulation showed a much weaker OR. The authors concluded that citrullinated a-enolase is a specific autoantigen that links smoking and genetic risk factors in RA.
The ongoing quest for other genes
Although the shared epitope is the strongest known genetic factor in RA, it is clearly not the only one. Over the past two decades, there has been continuous effort to identify additional genetic risk factors for RA, both within and without the HLA region. Notable studies published during the last year are discussed below.
In a case-control study involving 855 RA patients and 977 controls, Vignal et al. [46 ] have identified 18 SNPs in 14 non-DRB1 HLA region genes that showed strong association with RA. After multivariate logistic regression analysis, the model was narrowed down to DRB1 and three markers, two of which were independent of DRB1 and one (DQA2) was found to be in linkage disequilibrium with a shared epitope-coding allele (HLA-DRB1Ã0101). Thus, in addition to identifying new RAassociated SNPs, this study argues against a direct effect of the HLA-DQ locus, a question that has long been a subject of controversy.
A recent study implicated another HLA region gene, MICA (MHC class I polypeptide-related sequence A), as an RA susceptibility locus [47 ] . Using both familybased and case-control cohorts, a significant association between RA and MICA-250, independent from shared epitope-coding alleles, was identified. Interestingly, MICA-250 was found to be in complete linkage disequilibrium with a MICA functional variant, previously shown to confer differential allelic affinity between MICA and its receptor (NKG2D).
Associations with FCGR (the locus that codes Fcg receptors) have been investigated in 2049 RA patients and 1156 controls by Robinson et al.
[48], with particular attention to the FCGR3A-158F/V genotype. A modest association (OR 1.2) with homozygosity for FCGR3A-158F/V was found when all RA patients were analyzed. Somewhat stronger association was found when only men were considered (OR 1.7). No evidence for interaction with the HLA-DRB1 shared epitope was found.
A negative yet important study on PADI4-RA association has been recently reported by Burr et al. [49 ] . Polymorphisms in the PADI4 gene have been previously shown to correlate with RA susceptibility in Eastern Asians, but their contribution to disease risk in white populations remained unclear. In the largest study of its kind, this group enrolled over 19 000 UK participants. No association with RA was demonstrated for the PADI4_94 SNP (as well as 56 other PADI4 SNPs). Although significant interaction between shared epitope and PTPN22 was detected in ACPA-positive RA patients, there was no interaction of the PADI4_94 SNP with either PTPN22 R620W SNP or shared epitope-coding alleles. Metaanalysis of five published studies confirmed the lack of association between PADI4_94 and RA in European populations.
Another study [50] reported an association between b2-adrenergic receptor polymorphism and RA. Specifically, strong associations were found with receptor variants expressing arginine at position 16. Individuals with Arg16-coding alleles had earlier age of disease onset and Arg16/Arg16 homozygosity was associated with greater incidence of ACPA. Another interesting observation in this study is a possible interaction between Arg16 and the shared epitope in disease risk.
An intriguing study implicating another non-HLA gene in RA has focused on a member of the cytochrome P450 gene family, CYP1A2. Cornelis et al. [51 ] studied the association between a common CYP1A2 polymorphism (À163 A>C) and RA in over 32 000 Korean participants. The OR of RA among carriers of a low-inducible allele was found to be 1.11 in shared epitope-negative individuals, 0.82 among shared epitope heterozygotes and 0.32 in individuals homozygous for shared epitopecoding HLA-DRB1 alleles. The significance of these findings is dual: CYP1A2 plays a role in oxidative stress, an aberration that has been long implicated in RA; CYP1A2 is a downstream effector enzyme in the aryl hydrocarbon receptor pathway, which mediates the xenobiotic effect of various polycyclic aromatic hydrocarbons, including those found in tobacco, and plays a role in autoimmunity in mice [6, 7] . If confirmed in other ethnic populations, the finding reported by Cornelis et al. 
Conclusion
The shared epitope is the single most significant genetic risk factor for RA. Although the mechanistic basis of shared epitope-RA association is unknown, progress made in the last several years and new observations made during the period reviewed here help better mapping of the main genetic and environmental players, which cooperate with the shared epitope or antagonize it. The knowledge recently gained could open new research directions that might help us better understand the enigmatic role of the shared epitope in the etiopathogenesis of RA.
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